Working with the NHS
At Bristol-Myers Squibb, we recognise the significant challenges facing the NHS. The public rightly want fast access to high quality care at a time and place that is convenient to them.
At the same time, the global recession means budgets are increasingly constrained. The challenge for the NHS, therefore, is to meet these public expectations with tighter resources.
We believe our portfolio of existing and pipeline medicines can be part of the solution to these challenges. These new medicines will offer opportunities for the NHS to provide patients with better outcomes and better quality of life. Yet we also recognise that new treatments will present challenges to the NHS.
New medicines often increase the upfront cost of healthcare. They may also require staff training, new capacity or changes to patient pathways. At a time when resources are stretched it is ever more important that the NHS gets the most out of the new medicines it invests in, in terms of both clinical outcomes and patient experience.
In recognition of this, our approach at Bristol-Myers Squibb is to work in partnership with the NHS to make sure it gets maximum value from our medicines.
Our teams are becoming more flexible when it comes to meeting customer needs rather than trying to apply a one-size-fits-all solution. In fact, we are now regularly having conversations with payers about providing a whole service and not just medicines.
Partnerships that bring value to the NHS
In order to meet its chosen strategy, every partnership entered into by Bristol-Myers Squibb with the NHS must be underpinned by four key undertakings:
- Bristol-Myers Squibb endeavours to continually develop medicines to meet true unmet medical need across a range of disease areas
- We are committed to enhancing clinical excellence through clinical research activities
- We will provide robust evidence on our medicines to support NHS decision makers
- Bristol-Myers Squibb is striving to improve its service delivery so that its medicines reach the right patients at the right time.
|NHS Trust Name||Joint Working Project||Documents|
|Velindre Cancer Centre (VCC),
Velindre NHS Trust
|Immuno-oncology Pathway Configuration (IPC)||Disclosure Statement|
|University College London
Hospitals (UCLH) on behalf of the
|Adverse Event Pathway Project (AEPP)||Disclosure Statement|
|Northern Centre for Cancer Care
(NCCC) as part of the Newcastle
upon Tyne Hospitals NHS Foundation Trust (NuTH)
|Reducing Time to Treatment Administration (RTTA)||Disclosure Statement|
|Hull and East Yorkshire Hospitals NHS Trust (HEY)||Adverse Event Pathway Project (AEPP)||Disclosure Statement|
|Hull and East Yorkshire Hospitals Trust||Pathway Improvement for Anti-Cancer Therapies.||Disclosure Statement|
|North West Coast Academic Health Science Network;
|Embedding new ways of working to
reduce Atrial Fibrillation (AF) related
strokes in the North West Coast
|Mount Vernon Cancer Centre (MVCC) at East
and North Hertfordshire NHS Trust
Pathway at Mount
Vernon Cancer Centre
|Staffordshire Sustainability and Transformation Partnership (STP)||Implementation of Staffordshire-wide Technology Enabled Care Services (TECS)
and a North Staffordshire Division Service Improvement Pilot
|Newcastle upon Tyne Hospitals NHS Trust||Reducing Time to Treatment Administration (RTTA) Phase 2 –
Moving from identifying the problem to improving treatment efficiencies
|Sheffield Teaching Hospitals NHS Foundation Trust||Developing a robust, appropriate clinical review model for oncology patients who are off (systemic anti-cancer) treatment to detect relapse promptly and manage late effects of (novel) therapies||Disclosure Statement|
|Poole Hospital NHS Foundation Trust (PHFT)||Implementation of a service improvement pilot to increase the clinical capacity and capability of Dorset Integrated Care System (ICS) to enable the optimisation of anticoagulation treatment for patients diagnosed with or at risk of Atrial Fibrilation (AF) and Venous Thromboemolism (VTE)||Disclosure Statement|